Sutro Biopharma
South San Francisco
About Sutro Biopharma
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $636.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:STRO
- Website: sutrobio.com
- Phone: 650-392-8412
Industries & Categories
Biotechnology, Information Technology, Medical
Social Profiles
Canonical: https://fsome.com/organization/sutro-biopharma-93054 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.